MatthewJosephWieduwiltMD

Oncology • Winston Salem, NC

Assistant Professor, Medicine, UCSD School of Medicine

Join to view full profile

Dr. Wieduwilt is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wieduwilt's full profile

Already have an account?

Office
Medical Center Blvd
Winston Salem, NC 27157
Phone+1 336-713-5440

Fax+1 336-713-5445

Education & Training

University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2008 - 2011
University of California (San Francisco)Residency, Internal Medicine, 2005 - 2008
University of Texas Southwestern Medical SchoolClass of 2005

Certifications & Licensure

NC State Medical License 2022 - 2025
CA State Medical License 2007 - 2023
OK State Medical License 2021 - 2023

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL Start of enrollment: 2012 Mar 01
Terminated
Phase 3
Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia Start of enrollment: 2012 Dec 13
Completed
Phase 3
A Phase I Study of IGN523 in Subjects With Relapsed or Refractory AML Start of enrollment: 2014 Feb 01
Completed
Phase 1
Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma Start of enrollment: 2014 Jan 01
Terminated
Phase 2
Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome Start of enrollment: 2016 May 17
Completed
Phase 1
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL) Start of enrollment: 2016 Mar 01
Terminated
Phase 1
Blinatumomab and Pembrolizumab for Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia With High Marrow Lymphoblasts Start of enrollment: 2017 Aug 04
Active, not recruiting
Phase 1, Phase 2
Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia Start of enrollment: 2019 May 08
Recruiting
Phase 2
Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia. Start of enrollment: 2020 Aug 05
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

53 citations
Sociodemographic disparities in chemotherapy and hematopoietic cell transplantation utilization among adult acute lymphoblastic and acute myeloid leukemia patients.
Brice Jabo, John Morgan, Maria Elena Martinez, Mark Ghamsary, Matthew J. Wieduwilt
Plos One. 2017-04-06
280 citations
Acute myeloid leukemia, version 3.2019
Martin S. Tallman, Eunice S. Wang, Jessica K. Altman, Frederick R. Appelbaum, Vijaya Raj Bhatt
Journal of the National Comprehensive Cancer Network. 2019-01-01
81 citations
CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a ra...
Jeffrey E. Lancet, Geoffrey L. Uy, Laura F. Newell, Tara L. Lin, Ellen K. Ritchie
The Lancet. Haematology. 2021-07-01

Abstracts/Posters

Blinatumomab in Combination with Pembrolizumab Is Safe for Adults with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia: University of California Hematolo...
Matthew J. Wieduwilt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart¬ Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients
Matthew J. Wieduwilt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (AML) with Prior Hypomethylatin...
Matthew J. Wieduwilt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Anal...
Matthew J. Wieduwilt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase 1b Dose Escalation Trial of Carfilzomib in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
Matthew J. Wieduwilt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Expert Discussion and Guidance on New Advances, Clinical Opportunities, and Current Challenges in Treating Adults with Ph-Negative Acute Lymphoblastic Leukemia
60th American Society of Hematology Annual Meeting - 11/30/2018

Press Mentions

Combination Therapy Achieves High Response in Ph+ ALLJune 5th, 2021
Young Chula Vista Man’s Blood Cancer Diagnosis Example of Challenges Facing Vulnerable Age GroupSeptember 30th, 2019
Inotuzumab Ozogamicin, Blinatumomab May Be Superior to Chemotherapy in Some Elderly Patients with B-cell ALLJune 5th, 2023